Immunotherapy Archives

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin’s Lymphoma. An undisclosed shareholder has just increased its position in the company by purchasing an additional 3.3 million shares, leading to a total of €19.2M private investment. Affimed Therapeutics is a NASDAQ-listed biotech […]

October 19, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Oct 2015

Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

This week, we’re leaving Paris and heading East to a city that’s 9 times bigger than the capital of France, it’s also the city we all call home here at Labiotech, Berlin. When someone thinks of Berlin, they think of the wall, the Fernsehturm (television tower) and its amazing nightlife (I can personally agree with this 😉 […]

October 16, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Oct 2015

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Ablynx – the Belgian nanobody biotech (which uses monoclonal antibodies of Alpacas), has now achieved it’s first pre-clinical milestone in its immuno-oncology partnership with MSD (Merck & Co). Now Ablynx has achieved proof of concept for one of the 17 Nanobodies being studied. Ablynx has therefore received the first €3.5M in milestone payments from MSD […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Oct 2015

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

Merck has opted to return its Phenylketonuria (PKU) candidates Kuvan and Peg-Pal back to BioMarin from January 2016. Merck will instead focus on other R&D areas, and will receive €340M in compensation (5 times the annual sales of Kuvan) with €180M for future Peg-Pal milestones. This appears to support the back-peddling trend of major Biotechs […]

October 2, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Will Roche lose its Worldwide Leading position in Cancer treatments?

Roche is the worldwide leader in cancer treatments, but it’s threatened by the increasing competition of biosimilars and the development of next-generation cancer drugs. Is there a risk for the “biggest Biotechnology company worldwide” to lose its leading position on the lucrative anti-cancer business? The Swiss giant makes massive amount of cash with its cancer treatments, […]

September 29, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 26 Sep 2015

Replimune smashes Oncolytic viral €26.8M series A financing round

Replimune is an Oxford (UK) biotech baby, having only been founded in April this year a spin-off of former US BioVex. Nonetheless, this hasn’t stopped its Series A finance round reaching up to €26.8M. Replimune’s focal research is in developing new immuno-oncology therapies using oncolytic viruses, inspired by BioVex-Amgen’s T-VEC success. Replimune was founded by […]

September 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

France’s leading Female Bio-entrepreneur joins board of Abivax

Dominique Costantini is one of France’s leading biotech figures, with over 20 years experience on boards, partnerships and business backing in some of the biotech industries leading brands. With a medical background specializing in immunology (from Paris V University), Costantini co-founded oncology focused Onxeo in 1997. Formerly known as BioAlliance Pharma, this biotech went public […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries. TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II […]

September 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Encouraging results from Tedopi Phase II trials in patients with brain metastases

French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain metastases. Announced at the World Conference on Lung Cancer in Denver (US), OSE Pharma revealed how Tedopi had shown interesting results in patients diagnosed with brain metastases from advanced non-small cell lung cancer. Advanced non-small […]

September 9, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 7 Sep 2015

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]

September 7, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Biotech of the week: Mologen, the Largest Publicly-listed Biotech of Berlin

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology

Innate Pharma receives $5M from its Monster-deal with BMS

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

Will Roche lose its Worldwide Leading position in Cancer treatments?

Replimune smashes Oncolytic viral €26.8M series A financing round

France’s leading Female Bio-entrepreneur joins board of Abivax

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

Encouraging results from Tedopi Phase II trials in patients with brain metastases

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!